HLB테라퓨틱스

115450KOSDAQ기타 전문 도매업

49.9 / 100

Reference Date: 2026-07-24

Financial Score10.5 / 40

News Sentiment20.4 / 25

Momentum7.0 / 20

Disclosure12.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 23.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Therapeutics operates three core business divisions: biopharma, cold chain, and electronics. Through numerous mergers and acquisitions since 2013, the company has diversified its business, and after divesting its electronics division in 2024, it continues to transition toward a biopharma-focused structure. Its main revenue streams come from vaccine pharmaceuticals and distribution fees.

Number of Employees

50people

Average Salary

48.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 12.754.0Point

PBR

0.88Industry Average 0.581.0Point

1.5x industry avg (risky)

ROE

-5.44Industry Average 2.090.0Point

Well below industry avg

Debt Ratio

16.44Industry Average 7.870.0Point

2.1x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲14.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲33.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -6.9% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 0Negative 1Average Sentiment Score 81.7

Positive
HLB테라퓨틱스, RGN-259 글로벌 3상 환자모집 완료
HLB테라퓨틱스의 RGN-259 치료제가 글로벌 임상 3상 환자 모집을 성공적으로 완료하여 긍정적인 시장 반응을 기대할 수 있다.
Negative
HLB, 간암 신약 FDA 보완 요구에 줄줄이 ‘하한가’ [Why바이...
HLB테라퓨틱스의 간암 신약 '리보세라닙' FDA 승인 실패로 인해 주가가 급락했다.
Positive
HLB생명과학R&D, 상반기 5건 국책과제 선정…차세대 헴프 신약개발 ...
HLB테라퓨틱스의 R&D 부서가 상반기에 국책과제 5건 선정으로 연구 역량 강화를 보여주며 긍정적인 시장 반응을 이끌고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 1,736Won52-week high 3,98052-week low 1,451

1-month return0.0Point

1m -23.19% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02
Positive[기재정정]단일판매ㆍ공급계약체결2026-06-30
Neutral주식등의대량보유상황보고서(일반)2026-06-29